Bioequivalence and Bioavailability Forum • Effects and adverse effects

Effects and adverse effects [Design Issues]

posted by Helmut – Vienna, Austria, 2015-08-17 16:55 (3967 d 07:33 ago) – Posting: # 15283
Views: 4,779

BE-proff,

for effects and adverse effects ask your physician or pharmacist. See f.i. this presentation. Some more:

2×2×3 Full replicate design (RTR|TRT)
- Estimation of CV_wR and CV_wT.
  Suitable for both ABEL (EMA) / RSABE (FDA) and ABE.
  Less sampled blood volume compared to RTRT|TRTR and lower chance of dropouts.
- The EMA requires ≥12 evaluable subjects in sequence RTR. Practically not relevant (see this post).

2×3×3 Partial replicate design (RRT|RTR|TRR)
- Suitable for both ABEL (EMA) / RSABE (FDA) and ABE.
  Less sampled blood volume compared to RTRT|TRTR and lower chance of dropouts.
- Allows only estimation of CV_wR.
  Sometimes convergence issues if evaluated by FDA’s method for ABE.

2×4×2 Balaam’s design (RT|TR|RR|TT)
- Allows estimation of CV_wR and CV_wT.
  Suitable for both ABEL (EMA) / RSABE (FDA) and ABE.
  Less sampled blood volume compared to 3-period replicate designs and lower chance of dropouts.
- Very (!) low power compared to 3- and 4-period replicate designs. Only ½ of the subjects are used to assess BE; CV_wR and CV_wT are estimated from ¼ of the subjects.

Balanced Incomplete Block Designs (BIBD)
- Suitable for ABE.
  Generally only used in pilot or dose proportionality studies if >4 treatments are tested and >4 periods cannot be used due to blood volume restrictions and/or expected dropout-rate.
  Number of periods < number of treatments.
- Lower power compared to higher-order crossovers (Latin Squares or William’s designs, where number of periods = number of treatments).

Notes:

Balaam’s design and the 4-sequence 4-period replicate designs (2×4×2 RTTR|TRRT|RRTT|TTRR) are currently (v1.2-08 of 2015-07-10) not implemented in PowerTOST’s functions for ABEL and RSABE.
The completely randomized 4-period replicate (RTTR|TRRT|RRTT|TTRR|RTRT|TRTR) is not implemented at all. Doesn’t matter – haven’t seen one in ages.

—
Dif-tor heh smusma 🖖🏼 Довге життя Україна!
Helmut Schütz

[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

Indications for different BE-designs BE-proff 2015-08-17 11:59 [Design Issues]
- Effects and adverse effectsHelmut 2015-08-17 14:55
  - Effects and adverse effects BE-proff 2015-08-18 08:26

Admin contact
23,655 posts in 4,993 threads, 1,572 registered users;
356 visitors (0 registered, 356 guests [including 24 identified bots]).
Forum time: 00:28 CEST (Europe/Vienna)

Don’t compromise yourself.
You are all you’ve got. Janis Joplin

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC

Ing. Helmut Schütz